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homozygous group are similar to the unadjusted results
(data not shown). Similarly, after adjusting for number
of mismatched HLA alleles (considering HLA-A, -B,
-C, -DRB1, -DQB1, and -DPB1, with a range of 0 to
8 total mismatches in the 391 patients), the effects asso-
ciatedwith the homozygous group are similar to the un-
adjusted results (data not shown).
In summary, the absence of functional CCR5 in
marrow donors may be associated with less GVHD.
With only 8 patients having a homozygous donor,
these preliminary results are in need of larger numbers.
Therefore, we propose screening the sample reposi-
tory from the National Marrow Donor Program
Foundation to identify additional patients with
a CCR5D32 homozygous donor. Currently CCR5
antagonists are developed and approved for HIV
treatment [10]. Further studies may provide rationale
to develop novel treatments for GVHD.ACKNOWLEDGMENTS
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Graft and Leukemic Relapse
after Pediatric HCT
Wereadwith interest the letter fromTravi and col-
leagues [1] reporting results from their own institution
that differed from those we recently published in the
Journal [2]. The letter inquired whether differing dis-
tributions of demographics or conditioning regimens
might explain why the similar, contemporary samples
yielded contrasting findings on whether donor/recipi-
ent cytomegalovirus (CMV) serostatus affects the inci-
dence of leukemic relapse after pediatric hematopoietic
cell transplantation (HCT). Here we reply to the ques-
tion, and offer a potential explanation of our own.
After stating the traditional view, establishedbefore
the current era ofCMVpreemptive therapy, that ‘‘sero-
negative recipients with a seronegative donor (D2/
R2) have shown an improved outcome’’ after HCT,
Travi et al. [1] reported that, amongpediatric recipients
at their institution, D2/R2 grafts were not associated
with improved outcome, either in relapse or nonrelapse
mortality (NRM). In contrast, our study of a similar pe-
diatric sample [2] yielded the novel finding that D2/
R2 grafts were significantly associated with poorer
outcome (higher incidence of relapse, inferior re-
lapse-free survival [RFS]) than other grafts. Because re-
lapse was rarely detected by Travi et al. [1] after 2 years
posttransplant, we compared 2-year incidence by insti-
tution and serostatus, using Figure 1B fromTravi et al.
[1] and Figure 2 from our article [2]. At 2 years post-
HCT, the 2 samples had similar cumulative incidences
134 Biol Blood Marrow Transplant 16:132-133, 2009Letters to the Editorof NRM (which did not differ by D2/R2 serostatus)
and similar cumulative incidences of relapse in the
D2/R2 subgroup, but at our institution only, recipi-
ents of seropositive grafts (D1 and/or R1) had signif-
icantly reduced incidences of relapse.We interpret this
finding as evidence that certain conditions at our insti-
tution promoted the graft-versus-leukemia (GVL)
effect of HCT in our pediatric sample, specifically in
those recipients who received CMV-seropositive
grafts.
What conditions might have differed between our
2 institutions and accounted for the contrasting find-
ings?Travi et al. [1] suggested that the explanationmight
be found in the distribution of ethnicity (Caucasian
versus other), total body irradiation (TBI)-based condi-
tioning, or age in our 2 samples. To address this
suggestion, we examined whether the samples differed
on demographics or TBI use. We then investigated
whether the association between D2/R2 serostatus
and relapse in our sample became nonsignificant after
adjustment for age,TBI, or ethnicity,orwas significantly
modified by interaction with these characteristics.
Our sample had a higher proportion of Caucasians
(86.4% versus 74.3%, P\ .01), but TBI use was similar
(85.0% versus 81.9%) in the 2 samples. Whether they
differed in age could not be determined, because Travi
et al. [1] did not report an age distribution. In our pub-
lishedmodelof relapse [2],D2/R2 serostatus remained
significant after adjustment for age and other covariates;
the effect of serostatus did not vary with age. Further
analysis determined that TBI use was not associated
with relapse and did not modify the effect of serostatus.
Non-Caucasian ethnicity was not associated with
relapse, but appeared to enhance the effect of serostatus:
the cumulative incidence-based hazards ratio of relapse
with D2/R2 graft was 2.81 (95% confidence interval
[CI] 1.25-6.28) in Caucasians and 12.3 (2.94-51.4) in
non-Caucasians, compared to recipients of seropositive
grafts of any ethnicity. We regard the interaction
between serostatus and ethnicitywith caution, however,
because our sample had few non-Caucasian patients
(19/140), a biologic rationale for the interaction is lack-
ing, and the model’s fit was not appreciably improved
after stratifying seronegative graft by ethnicity. In sum-
mary, differences in demographics or TBI use are
unlikely to explain why an association between D2/
R2 graft and relapse was present in our sample but
not in that of Travi et al. [1].
We believe that a more compelling explanation for
why the 2 institutions obtained different results may be
found in their different methods of CMV surveillance.
At our institution, surveillance at the time was primar-
ily by viral culture, a less sensitive method than pp65
antigenemia or polymerase chain reaction (PCR),
used historically at the other institution [3]. Moreover,
the sensitivity of viral culture in our patients may have
been further reduced if the volume of blood culturedwas less than that typically used for adults. Less sensi-
tive surveillance may have delayed or reduced detec-
tion of CMV activation, which in turn, may have
delayed or reduced initiation of preemptive therapy.
As a result, exposure to subclinical CMV viremia
may have been prolonged, and ganciclovir may have
been initiated later or less often, among our recipients
of seropositive grafts than among similar patients at
the other institution. Recipients of seronegative grafts,
in contrast, would have been little affected by differ-
ences in sensitivity of CMV detection, because viremia
is far less common in that group. It is possible that
prolonged early exposure to subclinical CMV had a
stimulatory effect on natural killer (NK) and T cells
[4-7]. It is also possible that delayed or reduced
initiation of ganciclovir, a drug that can suppress T
cell proliferation [8] and delay T cell recovery [9],
benefitted repopulating T cells. Either possibility
could have enhanced the GVL effect in our recipients
of seropositive grafts.
We agree with Travi et al. [1] that a definitive
investigation of the effect of graft serostatus on the
outcome of pediatric HCT will require a large, multi-
center study. In fact, we formally proposed such a study
to the Center for International Blood and Marrow
Transplant Research (CIBMTR) in November 2008.
It must be recognized, however, that results from
a multicenter study will be conclusive only if the anal-
ysis controls for differences between centers, and also
within centers over time, in the methods of CMV sur-
veillance and CMVmanagement (preemptive therapy,
prophylaxis, or both). In addition, the choice of eligi-
bility criteria will be important. For conclusive results,
not only should all subjects be pediatric recipients
of primary, myeloablative, allogeneic HCT for acute
leukemia, but the primary analysis should exclude T
cell depleted or cord blood grafts, because in those
grafts, the effect of serostatus on incidence of relapse
might be abolished.ACKNOWLEDGMENTS
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a Complication of Chronic
Graft-Versus-Host Disease
The paraneoplastic retinopathies, first described
in 1976 [1], include cancer-associated retinopathy
(CAR) and melanoma-associated retinopathy
(MAR) [2]. Affected patients present with acute,
subacute, or chronic signs and symptoms of retinal
dysfunction [3]. Findings on retinal examination in-
clude attenuated vessels, ‘‘waxy’’ disc pallor, and ret-
inal pigment epithelial mottling, although at times
the exam is normal [4,5], and there are characteris-
tically no signs of inflammation [6]. Electroretino-
grams (ERGs) are typically abnormal, and negative
waveforms are common [3]. Pathogenic retinal anti-
bodies are often found in the serum of affected in-
dividuals.
Patients with CAR usually have coexisting solid
tumors involving the lung, ovaries, or colon [7]. Serum
from affected individuals may contain antibodies torecoverin, a calcium binding protein that controls
phosphorylation of rhodopsin in both rod and cone
photoreceptors [8,9].
Recently, a series of patients has been identified
with antibodies to transducin-a, a 40-kDa photorecep-
tor G-protein naturally expressed in rods and cones
(G. Adamus et al., unpublished data). Visual transdu-
cin is activated by rhodopsin following initial photon
capture, subsequently activating PDE6, and ultimately
photoreceptor membrane hyperpolarization [10].
Transducin is also present in other tissues and associ-
ated with tumors, including melanomas and carcino-
mas [11].
Here, we report the case of a 25-year-old woman
found to have new onset retinopathy in the setting of
chronic graft-versus-host disease (cGVHD) after allo-
geneic transplant, with subsequent demonstration of
serum anti-40-kDa antibodies that react with retinal
transducin-a. To our knowledge, this is the first report
of antibodies to transducin associated with retinopathy
as a complication of cGVHD.
The patient presented in May 2003 with pancyto-
penia, and was found to have FAB M4 acute myeloge-
nous leukemia (AML) with a 6;11 translocation.
Following successful standard induction chemotherapy
and 2 cycles of consolidation, she underwent an HLA-
matched, ABOmismatched unrelated donor (MMUD)
peripheral blood stem cell transplant (PBSCT) in Sep-
tember 2003. Short-course methotrexate (MTX) and
tacrolimus were utilized for GVHD prophylaxis.
In May 2005, early cytogenetic recurrence of leu-
kemia was noted by interphase fluorescein in situ hy-
bridization (FISH). Donor lymphocyte infusion
(DLI) was administered twice, followed by reinduction
chemotherapy in mid-August 2005. After entering
a second complete remission (CR2), the patient under-
went a second allogeneic PBSCT in October 2005,
from a 10/10 matched unrelated donor (MUD).
Following her second transplant, the patient devel-
oped grade III GVHD involving the skin and liver. She
was treated successfully with prednisone. A baseline
ophthalmologic evaluation in February 2006 disclosed
mild exposure keratopathy and buried optic nerve dru-
sen. For persistent pancytopenia, the patient received
a CD34-selected marrow boost in May 2006. Subse-
quent to this, tacrolimus was switched to sirolimus
because of hyperkalemia, renal insufficiency, and mi-
croangiopathy. Diarrhea developed in August 2006,
and after a month of persistent symptoms sirolimus
was discontinued, with prednisone and hydroxychlor-
oquine used for GVHD treatment. In March 2007,
worsening liver GVHD was successfully treated with
daclizumab, rituximab, and IVIg, followed by a return
to glucocorticoids and hydroxychloroquine for
GVHD control.
The patient was seen by an ophthalmologist in
November 2007, and found to have continued
